Wang Sen, Li Rumeng, He Suhui, He Lingge, Zhao Hang, Deng Xiaohong, Chen Zhangquan
Key Laboratory for Medical Molecular Diagnostic of Guangdong Province, Guangdong Medical University, Dongguan, Guangdong Province 523808, China.
Evid Based Complement Alternat Med. 2017;2017:9148523. doi: 10.1155/2017/9148523. Epub 2017 Dec 18.
As a Chinese traditional patent medicine, glycosides (TWG) have been approved by the China State Food and Drug Administration (Z32021007) for autoimmune and inflammatory diseases. Application of TWG leads to significant decrease of the inflammatory cytokines, such as IL-6, IL-1, and TNF-. However, little is known whether TWG could regulate the anti-inflammatory cytokines and what the mechanism is. Here, we found that TWG could induce the upregulation of IL-37 which is a new anti-inflammatory cytokine. Furthermore, the inhibitors of ERK1/2 and/or p38 MAPK pathways suppressed IL-37 expression induced by TWG, indicating that the two pathways took part in this process. In conclusion, TWG could upregulate the anti-inflammatory cytokine IL-37 and ERK1/2 and p38 MAPK signal pathways were involved in the upregulation of IL-37 induced by TWG. The results showed that TWG had a potent activity on promoting the expression of IL-37, a new anti-inflammatory cytokine, which help further understanding the anti-inflammatory mechanism for the clinical application of TWG in therapy of diseases.
作为一种中国传统专利药物，雷公藤多苷（TWG）已获得中国国家食品药品监督管理总局批准（Z32021007）用于自身免疫性和炎性疾病。TWG的应用可导致炎性细胞因子如IL-6、IL-1和TNF-显著减少。然而，关于TWG是否能调节抗炎细胞因子及其机制知之甚少。在此，我们发现TWG可诱导新型抗炎细胞因子IL-37的上调。此外，ERK1/2和/或p38 MAPK信号通路的抑制剂可抑制TWG诱导的IL-37表达，表明这两条信号通路参与了该过程。总之，TWG可上调抗炎细胞因子IL-37，且ERK1/2和p38 MAPK信号通路参与了TWG诱导的IL-37上调。结果表明，TWG在促进新型抗炎细胞因子IL-37表达方面具有强大活性，这有助于进一步理解TWG在疾病治疗中临床应用的抗炎机制。
